“I think for breast cancer, every few months there's something new and exciting,” the physician shared. “I think there's always some new technology, new drugs, or new study that comes out that changes our outlook."
“I realized breast surgery put me in the operating room, which I love to do, but it also allowed me to take care of my patients hands-on and I could follow my patients practically forever,” explained Dr. Karen Karsif.
The team at Dune Medical is heartbroken over the passing of Nancy M. Cappello, Ph.D. and would like to extend sincere condolences to her family, especially her husband Joseph Cappello, friends, colleagues, and supporters.
Lori Chmura, CEO of Dune Medical Devices, maker of the successful MarginProbe device is scheduled to present at the Canaccord Genuity Medical Technologies and Diagnostics Forum on Thursday, November 15th at 2:30 p.m. EST at the Westin Grand Central in New York, NY.
In alignment with their mission to ensure that every woman with a diagnosis of breast cancer has an opportunity to receive the most comprehensive care possible, Dune Medical recently sponsored SHARE at their annual tasting benefit night, A Second Helping of Life.
Dr. Jeffrey Falk, board certified Surgical Oncologist at St Johns Hospital in Detroit, recently shared his outstanding results reducing positive margin rates using MarginProbe in lumpectomy at ORBS by Design 2018.
Breast density is one of the most common reasons for failure of mammography to detect cancer and presents unique challenges for breast cancer patients and providers. Despite being a well-established independent risk factor for breast cancer(1), 95% of women do not know their breast density.
There has been much recent discussion around breast cancer in areas of breast density in relation to detection, and the latest observations in the field of genetics. A veteran breast surgeon, Dr. Erica Giblin, took some time to share her thoughts on the impact of both.
Capitalizing on the European Union Horizon 2020 research and innovation program, Dune Medical has completed the first phase in the development of its percutaneous soft tissue biopsy device.
It’s been one year since our relocation to Atlanta in August 2017. We have been incredibly busy these past 12 months, and here are some of the highlights!